Skip to main content Help with accessibility Skip to main navigation

Mirikizumab

Indication

Moderately to severely active ulcerative colitis (NICE TA925)

NICE TA925 - Mirikizumab for treating moderately to severely active ulcerative colitis

Red

Brand:

Nice TA:

925

Commissioning responsibility:

CCG

PbR excluded:

Yes

BNF chapter:
Gastro-intestinal system

Background

1.1 Mirikizumab is recommended as an option for treating moderately to severely active ulcerative colitis in adults when conventional or biological treatment cannot be tolerated, or the condition has not responded well enough or lost response to treatment, only if:

  • a tumour necrosis factor (TNF)‑alpha inhibitor has not worked (that is the condition has not responded well enough or has lost response to treatment) or

  • a TNF-alpha inhibitor cannot be tolerated or is not suitable and

  • the company provides it according to the commercial arrangement.

Recommendation

LSCMMG Recommendation:

Red

Reason for decision:

Specialist medicine

Supporting documents:

Decisions of Lancashire local decision making groups

BwD
BP
CSR
EL
FW
GP
MB
WL
Red
Red
Red
Red
Red
Red
Red
Red
What do the colours mean?

Last Updated: 11 - Jan - 2024